ProfileGDS5678 / 1459383_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 21% 20% 24% 21% 21% 27% 37% 21% 20% 20% 21% 22% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5113120
GSM967853U87-EV human glioblastoma xenograft - Control 22.4910121
GSM967854U87-EV human glioblastoma xenograft - Control 32.4822920
GSM967855U87-EV human glioblastoma xenograft - Control 42.510224
GSM967856U87-EV human glioblastoma xenograft - Control 52.4448721
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.566321
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6521627
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8364337
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4647321
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4711520
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4694320
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4639621
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.509122
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4910721